Craniospinal irradiation with boost to primary tumor site (and metastatic sites) is current
radiotherapy standard for most patients diagnosed with medulloblastoma (MB). This …

Results The median follow up was 8.1 years (1-16.3). The median age at start of PRT was
8.1 years (2.5-24.1). The percentage of patients undergoing a gross total resection (GTR) or …

BACKGROUND Report disease control, survival outcomes, and acute radiotherapy related
toxicity among young adult medulloblastoma patients who received proton craniospinal …

Purpose The aim of this study was to comprehensively review all studies examining clinical
outcomes of craniospinal irradiation with proton radiotherapy for medulloblastoma (MB) to …

Simple Summary Medulloblastoma is the most common malignant brain tumor in children.
Treatment is effective, but survivors often develop long-term sequelae that impact their …

Purpose/Objective (s) The aim of this study was to comprehensively review all studies
examining clinical outcomes of proton therapy for craniospinal irradiation of …

CRA9507 Background: Pediatric medulloblastoma (MB) is commonly cured with surgery,
chemotherapy and radiation. However, the late effects of radiotherapy can be disabling …

TaggedPAbstract Purpose: The aim of this study was to comprehensively review all studies
examining clinical outcomes of craniospinal irradiation with proton radiotherapy for …

Results Of 133 treated patients, 108 were alive at last follow-up (median 3.2 y, range 0.2–
8.9). Median age at diagnosis was 6.2 y (0.6–16.7). Sixty-four percent were female, and 21 …

Purpose We report disease control, survival outcomes, and treatment-related toxicity among
adult medulloblastoma patients who received proton craniospinal irradiation (CSI) as part of …